Documenti fondamentali

Visualizza tutta la documentazione

Vai a

M3071

Moclobemide

Name: Moclobemide
Brand: SIGMA
Price: 167 CHF

≥98% (HPLC), MAOI inhibitor, solid

Offerta disponibile

Sinonimo/i:

4-chloro-N-[2-(4-morpholinyl)ethyl]benzamide, Aurorix, Moclamine

Autenticati per visualizzare i prezzi organizzativi e contrattuali.

Scegli un formato

Cambia visualizzazione

Voi/SKU	Disponibilità	Prezzo
10 mg	Per conoscere la disponibilità, visualizza il carrello	CHF 167.00
50 mg	Per conoscere la disponibilità, visualizza il carrello	CHF 662.00

Informazioni su questo articolo

Formula empirica (notazione di Hill):

C₁₃H₁₇ClN₂O₂

Numero CAS:

71320-77-9

Peso molecolare:

268.74

UNSPSC Code:

12352200

PubChem Substance ID:

329817960

NACRES:

NA.77

MDL number:

MFCD00865388

Assay:

≥98% (HPLC)

Form:

solid

CHF 167.00

Per conoscere la disponibilità, visualizza il carrello

Richiedi un ordine personalizzato

Servizio Tecnico

Hai bisogno di aiuto? Il nostro team di scienziati qualificati è a tua disposizione.

Permettici di aiutarti

Proprietà

Nome del prodotto

Moclobemide, ≥98% (HPLC), solid

Quality Segment

100

assay

≥98% (HPLC)

form

solid

color

white

solubility

DMSO: >20 mg/mL

originator

Roche

storage temp.

room temp

SMILES string

Clc1ccc(cc1)C(=O)NCCN2CCOCC2

InChI

1S/C13H17ClN2O2/c14-12-3-1-11(2-4-12)13(17)15-5-6-16-7-9-18-10-8-16/h1-4H,5-10H2,(H,15,17)

InChI key

YHXISWVBGDMDLQ-UHFFFAOYSA-N

Descrizione

Biochem/physiol Actions

Moclobemide acts as a substrate for cytochrome P450 2C19 (CYP2C19). It also behaves as an inhibitor of cytochrome P450 2D6 (CYP2D6), cytochrome P450 1A2 (CYP1A2 and CYP2C19. Moclobemide is also involved in the increased expression of B-cell lymphoma 2 (BcL-2). It also causes neural stem cell (NSC) differentiation into serotoninergic neuron by extracellular‐regulated kinase (ERK) pathway.

Moclobemide is a reversible monoamine oxidase A inhibitor (MAOI); antidepressant.

Moclobemide is a reversible monoamine oxidase A inhibitor (MAOI); antidepressant. Elimination half-life in humans = 1 -3 hrs; absolute oral bioavailability. Unlike other MAO inhibitors, does not significantly increase blood pressure in humans upon combination with tyramine.

Features and Benefits

This compound is featured on the Dopamine and Norepinephrine Metabolism page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.

This compound was developed by Roche. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Confronta articoli simili

Visualizza il confronto per intero

Mostra le differenze

1 of 1

Questo articolo	M1946	M1821	1165248
Sigma-Aldrich M3071 Moclobemide	Sigma-Aldrich M1946 Anticorpo anti-monoammino ossidasi B (regione C-terminale)	Sigma-Aldrich M1821 Anticorpo anti-monoammino ossidasi B	USP 1165248 Debine Related Compound D
description ≥98% (HPLC), solid	description affinity isolated antibody, ~1.5 mg/mL, buffered aqueous solution	description ~1.5 mg/mL, affinity isolated antibody, buffered aqueous solution	description United States Pharmacopeia (USP) Reference Standard
form solid	form buffered aqueous solution	form buffered aqueous solution	form -
assay ≥98% (HPLC)	assay -	assay -	assay -
Quality Level 100	Quality Level 200	Quality Level 200	Quality Level -
storage temp. room temp	storage temp. −20°C	storage temp. −20°C	storage temp. room temp
solubility DMSO: >20 mg/mL	solubility -	solubility -	solubility -
originator Roche	originator -	originator -	originator -